Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Key Highlights
- ➤Axogen (AXGN) completes acquisition of BioCircuit Technologies and NerveTape™
- ➤BioCircuit expected to contribute approximately $6 million to fourth-quarter 2026 revenue
- ➤BioCircuit expected to contribute approximately $34 million to 2027 revenue
- ➤Acquisition contribution excluded from Axogen’s latest full-year 2026 guidance of at least 24% growth
- ➤Axogen maintains 2026 gross margin at least 73% and free-cash-positive outlook
Expert Statements
Michael Dale, President and Chief Executive Officer of Axogen
“This is a significant day for Axogen and the surgeons and patients we serve.”
Michael Dale, President and Chief Executive Officer of Axogen
“NerveTape represents a new standard of care as the first sutureless nerve repair option—one that is simpler, faster, and more effective than microsuturing.”
Michael Dale, President and Chief Executive Officer of Axogen
“This innovative technology directly addresses surgeons’ everyday need to repair nerves and aligns perfectly with Axogen’s mission to make the restoration of peripheral nerve function an expected standard of care.”
Michael Dale, President and Chief Executive Officer of Axogen
“It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape’s full potential.”
ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.
“This is a significant day for Axogen and the surgeons and patients we serve,” said Michael Dale, President and Chief Executive Officer of Axogen. “NerveTape represents a new standard of care as the first sutureless nerve repair option—one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons’ everyday need to repair nerves and aligns perfectly with Axogen’s mission to make the restoration of peripheral nerve function an expected standard of care. It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape’s full potential.”
Get started
Create a free account to read the full story.